{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=5", "query": { "condition": "Hepatitis C Virus Infection", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 901, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T23:32:57.817Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00958763", "title": "Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Motivational Interviewing, Single - MIS", "type": "BEHAVIORAL" }, { "name": "Motivational Interviewing Group", "type": "BEHAVIORAL" }, { "name": "Usual Care Group - UCG", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 219, "start_date": "2006-03", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2009-08-13", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 3, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00958763" }, { "nct_id": "NCT01821963", "title": "Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection" ], "interventions": [ { "name": "Pegylated Interferon Alfa 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 1, "start_date": "2013-04", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01821963" }, { "nct_id": "NCT01332552", "title": "A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "GSK2485852 70 mg", "type": "DRUG" }, { "name": "GSK2485852 420 mg", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "GSK2485852 630 mg", "type": "DRUG" }, { "name": "GSK2485852 70 mg + Ritonavir 100mg", "type": "DRUG" }, { "name": "GSK2485852 210 mg +Ritonavir 100mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 27, "start_date": "2011-01-14", "completion_date": "2011-04-06", "has_results": false, "last_update_posted_date": "2017-07-07", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 5, "location_summary": "Anaheim, California • Orlando, Florida • Lenexa, Kansas + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Willingboro", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332552" }, { "nct_id": "NCT05717400", "title": "Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Velpatasvir", "type": "DRUG" }, { "name": "Voxilaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-03-17", "completion_date": "2024-08-29", "has_results": true, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05717400" }, { "nct_id": "NCT00008463", "title": "A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Interferon alfa-2a", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 132, "start_date": "2000-11", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 24, "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 12 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008463" }, { "nct_id": "NCT00547716", "title": "Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Omega-3 Fatty Acids", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo comparator", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "University of Missouri, Kansas City", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 2, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00547716" }, { "nct_id": "NCT02292706", "title": "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "LDV/SOF", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" }, { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "Other SOF-Based Regimen", "type": "DRUG" }, { "name": "Ineligible parent treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1609, "start_date": "2014-12-29", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 77, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02292706" }, { "nct_id": "NCT01691235", "title": "SIMpill Medication Dispensing Device in the Treatment of HCV", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "SIMpill device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2012-09", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2014-10-08", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01691235" }, { "nct_id": "NCT01846455", "title": "Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatic Failure", "Hepatic Impairment", "Chronic Hepatitis C Infection With Hepatic Coma" ], "interventions": [ { "name": "2.0mg Buprenorphine/0.5mg Naloxone", "type": "DRUG" }, { "name": "Promethazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indivior Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2012-09", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2016-10-24", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 3, "location_summary": "Hialeah, Florida • Orlando, Florida • San Antonio, Texas", "locations": [ { "city": "Hialeah", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01846455" }, { "nct_id": "NCT04493385", "title": "The Hepatitis C Transplant Collaborative", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Transplant; Failure, Heart", "Hepatitis C" ], "interventions": [], "intervention_types": [], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2019-09-16", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-06T23:32:57.817Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493385" } ] }